22 research outputs found
Cortico-ponto-cerebellar pathway in rats. An anatomical study of the somatosensory cortical input to the cerebellum
Cortico-ponto-cerebellar pathway is one of the major subcortical pathways linking sensory cortical areas with distant motor regions of the brain. In this thesis I focus on the projections from the primary somatosensory cortex in order to understand the principles in the organisation of this pathway in rats.
Primary somatosensory cortex in rats contains aggregates of granule cells in layer IV, named "barrels" by Woolsey and Van der Loos (1970). There are about 32 whiskers and an equal number of large cortical barrels within the posteromedial barrel subfield (PMBSF) in the primary somatosensory cortex. In addition to its cortical representation the peripheral organisation of the whiskers is replicated in other stations within the afferent pathway, the trigeminal nuclei and the thalamus. This organisation is easily identified both anatomically and physiologically. Therefore rat somatosensory system can serve as a model system to study sensory-motor integration.
I mapped terminals from small regions of the primary somatosensory cortex of rats (within and surrounding the PMBSF) in the pontine nuclei using the anterograde tracers Phaseolus vulgaris leucoagglutinin, biocytin and biotinilated dextran-amine. The results demonstrate that cells in layer Vb of all the cortical barrels project to the ipsilateral pons. Most barrel columns terminate within the same set of pontine nuclei with slight medio-lateral shifts in their termination zones. The most rostral, smaller barrel columns and the cortical regions representing intervibrissal fur project bilaterally. This dichotomy is not present in corticotectal projections. Both small and large barrel columns as well as the less granular zones of the somatosensory cortex project to the deep layers of the ipsilateral superior colliculus. Retrograde tracing with fluorescent latex beads demonstrated that at least 70% of layer Vb cells in the primary somatosensory cortex in rats send collaterals to the deep layers of the superior colliculus and the pontine nuclei.
Pontine nuclei project as mossy fibres onto the cerebellar cortex. These projections are predominantly contralateral but there are also ipsilateral mossy fibre terminals. Some pontine cells in cats are known to send axons that collateralise within the cerebellar white matter and supply the ipsilateral as well as the contralateral cerebellar cortex (Rosina and Provini, 1982). The experiments in the third chapter were designed to analyse whether and to what extent the axons of the pontine cells in rats, which receive somatosensory cortical inputs related to the whiskers, bifurcate. Whisker sensitive patches in lobules VII, IX and Crus I of the cerebellar cortex were injected with differently coloured fluorescent beads. Both sides of pontine nuclei contained large numbers of retrogradely labelled cells, a small percentage of which was double labelled
Recommended from our members
Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.
OBJECTIVE: The English Bowel Cancer Screening Programme (BCSP) recommends 3 yearly colonoscopy surveillance for patients at intermediate risk of colorectal cancer (CRC) postpolypectomy (those with three to four small adenomas or one ≥10 mm). We investigated whether faecal immunochemical tests (FITs) could reduce surveillance burden on patients and endoscopy services. DESIGN: Intermediate-risk patients (60-72 years) recommended 3 yearly surveillance were recruited within the BCSP (January 2012-December 2013). FITs were offered at 1, 2 and 3 years postpolypectomy. Invitees consenting and returning a year 1 FIT were included. Participants testing positive (haemoglobin ≥40 µg/g) at years one or two were offered colonoscopy early; all others were offered colonoscopy at 3 years. Diagnostic accuracy for CRC and advanced adenomas (AAs) was estimated considering multiple tests and thresholds. We calculated incremental costs per additional AA and CRC detected by colonoscopy versus FIT surveillance. RESULTS: 74% (5938/8009) of invitees were included in our study having participated at year 1. Of these, 97% returned FITs at years 2 and 3. Three-year cumulative positivity was 13% at the 40 µg/g haemoglobin threshold and 29% at 10 µg/g. 29 participants were diagnosed with CRC and 446 with AAs. Three-year programme sensitivities for CRC and AAs were, respectively, 59% and 33% at 40 µg/g, and 72% and 57% at 10 µg/g. Incremental costs per additional AA and CRC detected by colonoscopy versus FIT (40 µg/g) surveillance were £7354 and £180 778, respectively. CONCLUSIONS: Replacing 3 yearly colonoscopy surveillance in intermediate-risk patients with annual FIT could reduce colonoscopies by 71%, significantly cut costs but could miss 30%-40% of CRCs and 40%-70% of AAs. TRIAL REGISTRATION NUMBER: ISRCTN18040196; Results
Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening
This is a summary of independent research funded by the National Institute for Health. Research (NIHR)’s Programme Grants for Applied Research Programme (RP-PG-0609–10106
Self-Management education for adults with poorly controlled epILEpsy (SMILE (UK)): a randomised controlled trial protocol
This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.National Institute for Health Research Health Technology Assessment Programme; reference 09/165/01
213 The UK Flexible Sigmoidoscopy Screening Trial: Uptake and Outcomes of First Round Faecal Occult Blood Testing in the English NHS Bowel Cancer Screening Programme
Remote monitoring of atrial fibrillation recurrence using mHealth technology (REMOTE-AF)
Aims: This proof-of-concept study sought to evaluate changes in heart rate (HR) obtained from a consumer wearable device and compare against implantable loop recorder (ILR)-detected recurrence of atrial fibrillation (AF) and atrial tachycardia (AT) after AF ablation. Methods and results: REMOTE-AF (NCT05037136) was a prospectively designed sub-study of the CASA-AF randomized controlled trial (NCT04280042). Participants without a permanent pacemaker had an ILR implanted at their index ablation procedure for longstanding persistent AF. Heart rate and step count were continuously monitored using photoplethysmography (PPG) from a commercially available wrist-worn wearable. Photoplethysmography-recorded HR data were pre-processed with noise filtration and episodes at 1-min interval over 30 min of HR elevations (Z-score = 2) were compared with corresponding ILR data. Thirty-five patients were enrolled, with mean age 70.3 ± 6.8 years and median follow-up 10 months (interquartile range 8–12 months). Implantable loop recorder analysis revealed 17 out of 35 patients (49%) had recurrence of AF/AT. Compared with ILR recurrence, wearable-derived elevations in HR ≥ 110 beats per minute had a sensitivity of 95.3%, specificity 54.1%, positive predictive value (PPV) 15.8%, negative predictive value (NPV) 99.2%, and overall accuracy 57.4%. With PPG-recorded HR elevation spikes (non-exercise related), the sensitivity was 87.5%, specificity 62.2%, PPV 39.2%, NPV 92.3%, and overall accuracy 64.0% in the entire patient cohort. In the AF/AT recurrence only group, sensitivity was 87.6%, specificity 68.3%, PPV 53.6%, NPV 93.0%, and overall accuracy 75.0%. Conclusion: Consumer wearable devices have the potential to contribute to arrhythmia detection after AF ablation. Study Registration: ClinicalTrials.gov Identifier: NCT05037136 https://clinicaltrials.gov/ct2/show/NCT0503713
283 UK Flexible Sigmoidoscopy Screening Trial: Colorectal Cancer Incidence and Mortality Rates at 11 Years After a Single Screening Examination
Self-Management education for adults with poorly controlled epILEpsy (SMILE): a randomised controlled trial protocol:The 1st EAN Congress in Berlin, Germany
Biomarkers as predictors of recurrence of atrial fibrillation post ablation: an updated and expanded systematic review and meta-analysis
Background:
A high proportion of patients undergoing catheter ablation (CA) for atrial fibrillation (AF) experience recurrence of arrhythmia. This meta-analysis aims to identify pre-ablation serum biomarker(s) associated with arrhythmia recurrence to improve patient selection before CA.
Methods:
A systematic approach following PRISMA reporting guidelines was utilised in libraries (Pubmed/Medline, Embase, Web of Science, Scopus) and supplemented by scanning through bibliographies of articles. Biomarker levels were compared using a random-effects model and presented as odds ratio (OR). Heterogeneity was examined by meta-regression and subgroup analysis.
Results:
In total, 73 studies were identified after inclusion and exclusion criteria were applied. Nine out of 22 biomarkers showed association with recurrence of AF after CA. High levels of N-Terminal-pro-B-type-Natriuretic Peptide [OR (95% CI), 3.11 (1.80–5.36)], B-type Natriuretic Peptide [BNP, 2.91 (1.74–4.88)], high-sensitivity C-Reactive Protein [2.04 (1.28–3.23)], Carboxy-terminal telopeptide of collagen type I [1.89 (1.16–3.08)] and Interleukin-6 [1.83 (1.18–2.84)] were strongly associated with identifying patients with AF recurrence. Meta-regression highlighted that AF type had a significant impact on BNP levels (heterogeneity R2 = 55%). Subgroup analysis showed that high BNP levels were more strongly associated with AF recurrence in paroxysmal AF (PAF) cohorts compared to the addition of non-PAF patients. Egger’s test ruled out the presence of publication bias from small-study effects.
Conclusion:
Ranking biomarkers based on the strength of association with outcome provides each biomarker relative capacity to predict AF recurrence. This will provide randomised controlled trials, a guide to choosing a priori tool for identifying patients likely to revert to AF, which are required to substantiate these findings
Remote monitoring of atrial fibrillation recurrence using mHealth technology (REMOTE-AF)
Aims: This proof-of-concept study sought to evaluate changes in heart rate (HR) obtained from a consumer wearable device and compare against implantable loop recorder (ILR)-detected recurrence of atrial fibrillation (AF) and atrial tachycardia (AT) after AF ablation. Methods and results: REMOTE-AF (NCT05037136) was a prospectively designed sub-study of the CASA-AF randomized controlled trial (NCT04280042). Participants without a permanent pacemaker had an ILR implanted at their index ablation procedure for longstanding persistent AF. Heart rate and step count were continuously monitored using photoplethysmography (PPG) from a commercially available wrist-worn wearable. Photoplethysmography-recorded HR data were pre-processed with noise filtration and episodes at 1-min interval over 30 min of HR elevations (Z-score = 2) were compared with corresponding ILR data. Thirty-five patients were enrolled, with mean age 70.3 ± 6.8 years and median follow-up 10 months (interquartile range 8–12 months). Implantable loop recorder analysis revealed 17 out of 35 patients (49%) had recurrence of AF/AT. Compared with ILR recurrence, wearable-derived elevations in HR ≥ 110 beats per minute had a sensitivity of 95.3%, specificity 54.1%, positive predictive value (PPV) 15.8%, negative predictive value (NPV) 99.2%, and overall accuracy 57.4%. With PPG-recorded HR elevation spikes (non-exercise related), the sensitivity was 87.5%, specificity 62.2%, PPV 39.2%, NPV 92.3%, and overall accuracy 64.0% in the entire patient cohort. In the AF/AT recurrence only group, sensitivity was 87.6%, specificity 68.3%, PPV 53.6%, NPV 93.0%, and overall accuracy 75.0%. Conclusion: Consumer wearable devices have the potential to contribute to arrhythmia detection after AF ablation. Study Registration: ClinicalTrials.gov Identifier: NCT05037136 https://clinicaltrials.gov/ct2/show/NCT0503713